Review
Medical Laboratory Technology
Yamin Liang, Lu Li, Yanmei Chen, Jinyan Xiao, Dangheng Wei
Summary: The PD-1/PD-L1 pathway is crucial in immune responses and cancer therapy, but may accelerate the progression of atherosclerosis in some patients.
CLINICA CHIMICA ACTA
(2021)
Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong, Caiyun Zhong
Summary: This article discusses the role of immune checkpoint blockade in cancer treatment and explores the modulation of immune checkpoint proteins by phytochemicals and their combination effects with immune checkpoint inhibitors in various malignancies.
PHYTOTHERAPY RESEARCH
(2023)
Review
Medicine, Research & Experimental
Elina Khatoon, Dey Parama, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Summary: Ovarian cancer is a deadly gynecological cancer with a low survival rate. Recent advancements in immunotherapy, particularly targeting the PD-1/PD-L1 axis, have shown promise in enhancing anti-tumor activity. Combinatorial treatment with small molecule inhibitors has also shown improved efficacy.
Review
Biochemistry & Molecular Biology
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
Summary: Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Review
Oncology
Chinmoy Ghosh, Gary Luong, Yue Sun
Summary: Immune checkpoint blockade is a promising strategy for treating cancer by reactivating anti-tumor immunity, but the response rates and resistance towards current anti-PD-1/PD-L1 therapies remain challenges. New perspectives are needed to overcome these hurdles for successful cancer treatment.
Review
Immunology
Mohammad Jalili-Nik, Arash Soltani, Baratali Mashkani, Houshang Rafatpanah, Seyed Isaac Hashemy
Summary: Immunotherapy through immune checkpoints blockade has revolutionized the treatment of solid tumors. Blockade of PD-1 and its ligand has shown promising results in clinical studies, with ongoing investigations into the potential therapeutic effects of PD-1 inhibition in ATLL patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Biochemistry & Molecular Biology
Ewa Surmiak, Katarzyna Magiera-Mularz, Bogdan Musielak, Damian Muszak, Justyna Kocik-Krol, Radoslaw Kitel, Jacek Plewka, Tad A. Holak, Lukasz Skalniak
Summary: This article compares representative molecules from different classes in terms of their PD-1/PD-L1 dissociation capacity and in vitro bioactivity. Recent discoveries underscore important differences in the mechanisms of action of these molecules, with one principal feature to consider being the eventual human PD-L1 specificity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Edyta Zyla, Bogdan Musielak, Tad A. Holak, Grzegorz Dubin
Summary: Researchers have reported the crystal structure of a macrocyclic peptide inhibitor (peptide 104) bound to PD-L1, which shows a unique binding mode compared to another peptide of the same family. The binding mode is primarily driven by extensive hydrophobic interactions at the center of the binding surface and an electrostatic patch at the side. A sulfur/pi interaction supports the binding of the macrocycle to the receptor.
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Tianrui Yang, Ziren Kong, Wenbin Ma
Summary: Immune checkpoint inhibitors have revolutionized tumor immunotherapy, but face challenges in the treatment of glioblastoma due to its unique immunosuppressive characteristics. Recent clinical studies are focusing on combination therapies involving standard treatments, targeted therapies, and other immunotherapies to improve outcomes for patients with GBM.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Federica Costa, Rosanna Vescovini, Valentina Marchica, Paola Storti, Laura Notarfranchi, Benedetta Dalla Palma, Denise Toscani, Jessica Burroughs-Garcia, Maria Teresa Catarozzo, Gabriella Sammarelli, Nicola Giuliani
Summary: The study found that MM and SMM patients share a similar PD-L1/PD-1 bone marrow immune profile, suggesting that SMM patients could be an interesting target for PD-L1/PD-1 inhibition therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Marina Bolzoni, Denise Toscani, Federica Costa, Emanuela Vicario, Franco Aversa, Nicola Giuliani
IMMUNOLOGY LETTERS
(2019)
Article
Immunology
E. Ferretti, A. L. Horenstein, C. Canzonetta, F. Costa, F. Morandi
IMMUNOLOGY LETTERS
(2019)
Article
Medicine, Research & Experimental
Rituparna Das, Noffar Bar, Michelle Ferreira, Aaron M. Newman, Lin Zhang, Jithendra Kini Bailur, Antonella Bacchiocchi, Harriet Kluger, Wei Wei, Ruth Halaban, Mario Sznol, Madhav V. Dhodapkar, Kavita M. Dhodapkar
JOURNAL OF CLINICAL INVESTIGATION
(2018)
Review
Hematology
Marina Bolzoni, Denise Toscani, Paola Storti, Valentina Marchica, Federica Costa, Nicola Giuliani
EXPERT REVIEW OF HEMATOLOGY
(2018)
Article
Oncology
F. Morandi, D. Marimpietri, A. L. Horenstein, M. Bolzoni, D. Toscani, F. Costa, B. Castella, A. C. Faini, M. Massaia, V. Pistoia, N. Giuliani, F. Malavasi
Review
Immunology
Fabio Morandi, Alberto L. Horenstein, Federica Costa, Nicola Giuliani, Vito Pistoia, Fabio Malavasi
FRONTIERS IN IMMUNOLOGY
(2018)
Letter
Hematology
Paola Storti, Luca Agnelli, Benedetta dalla Palma, Katia Todoerti, Valentina Marchica, Fabrizio Accardi, Gabriella Sammarelli, Federica Deluca, Denise Toscani, Federica Costa, Emanuela Vicario, Giannalisa Todaro, Eugenia Martella, Antonino Neri, Nicola Giuliani
Review
Cell Biology
Federica Costa, Benedetta Dalla Palma, Nicola Giuliani
Review
Oncology
Federica Costa, Valentina Marchica, Paola Storti, Fabio Malavasi, Nicola Giuliani
Summary: Despite the debated use of PD-L1/PD-1 blockade in multiple myeloma (MM) patients, data on PD-1/PD-L1 expression profile and its potential link with CD38 pathways suggests a combined therapeutic approach could improve anti-tumoral effects in MM patients. Further studies are needed to clarify discrepancies in PD-1/PD-L1 distribution within the bone marrow microenvironment and to determine the efficacy of PD-1/PD-L1 blockade in reversing myeloma immune suppression and inhibiting myeloma cell survival.
Review
Biochemistry & Molecular Biology
Valentina Marchica, Federica Costa, Gaetano Donofrio, Nicola Giuliani
Summary: Multiple myeloma is a hematologic malignancy that depends on the microenvironment, and despite improvements in survival with new drugs, drug resistance and relapse remain issues, necessitating the development of new treatment strategies. Oncolytic virotherapy shows promise in cancer treatment, with various human viruses being studied in preclinical models and in clinical trials for MM patients, while the use of non-human viruses is also being explored to potentially avoid immune responses that could reduce efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Gaetano Donofrio, Valentina Franceschi, Francesca Macchi, Luca Russo, Anna Rocci, Valentina Marchica, Federica Costa, Nicola Giuliani, Carlo Ferrari, Gabriele Missale
Summary: COVID-19, caused by the highly infectious coronavirus SARS-CoV-2, is a global ongoing pandemic that has triggered intense scientific research on developing vaccines. Efforts are focused on quantifying neutralizing antibodies induced by vaccination to validate protection and control the pandemic, with a simplified neutralization assay being developed for easier implementation in medical laboratories. This innovative approach aims to improve the vaccination campaign and adapt to different coronavirus variants for enhanced efficacy.
Article
Oncology
Martina Chiu, Denise Toscani, Valentina Marchica, Giuseppe Taurino, Federica Costa, Massimiliano G. Bianchi, Roberta Andreoli, Valentina Franceschi, Paola Storti, Jessica Burroughs-Garcia, Rosa Alba Eufemiese, Benedetta Dalla Palma, Nicoletta Campanini, Eugenia Martella, Cristina Mancini, Jixiu Shan, Michael S. Kilberg, Giovanna D'Amico, Erica Dander, Luca Agnelli, Giancarlo Pruneri, Gaetano Donofrio, Ovidio Bussolati, Nicola Giuliani
Letter
Hematology
Benedetta Dalla Palma, Valentina Marchica, Mario Pedrazzoni, Fabrizio Accardi, Laura Notarfranchi, Matteo Goldoni, Federica De Luca, Federica Costa, Paola Storti, Denise Toscani, Gabriella Sammarelli, Sabrina Bonomini, Franco Aversa, Nicola Giuliani
BRITISH JOURNAL OF HAEMATOLOGY
(2018)
Review
Endocrinology & Metabolism
Fabrizio Accardi, Denise Toscani, Federica Costa, Franco Aversa, Nicola Giuliani
CALCIFIED TISSUE INTERNATIONAL
(2018)